Table 4.
Data on the use of ICSs from national and international bronchiectasis registries
| Author | Registry | n | Age, years | COPD (%) | Asthma (%) | ICSs (%) |
|---|---|---|---|---|---|---|
| Dhar et al. [47]a | Indian Registry | 2195 | 56 (41–66] | 5.3 | 2.5 | 63.2 |
| Martínez-García et al. [3] | Spanish BE Research Registry (RIBRON) | 1912 | 67.6 (±15) | 10.9 | 7.8 | 66.7 |
| Aksamit et al. [49] | US BE Research Registry | 1826 | 64 (±14) | 20 | 25 | 39 |
| Visser et al. [122] | Australian BE Registry | 589 | 71 (64–77) | 3.4 | 3.7 | – |
| Lee et al. [123] | KMBARC | 598 | 66 (60–72) | 37.8 | 22.4 | – |
| Polverino et al.b [124] | EMBARC | 18,927 | 16.6b | 8.7b | 53.1 |
BE bronchiectasis, ICSs inhaled corticosteroids, LABA long-acting β2-agonist
aIn 56.6% of patients, this treatment was a fixed combination of an ICS with a LABA. This finding might be in part driven by the availability of ICSs in India and their relatively low cost in a healthcare system where patients are required to pay for their medications themselves
bData from EMBARC etiology were extracted from Lee et al. [123]